These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 30060397)

  • 1. Response to 'On vascular calcification prevention with phosphonoformate and bisphosphonates'.
    Lomashvili KA; O'Neill WC
    Kidney Int; 2009 Jun; 75(12):1356. PubMed ID: 30060397
    [No Abstract]   [Full Text] [Related]  

  • 2. The crossover of bisphosphonates to cancer therapy.
    Sun M; Iqbal J; Singh S; Sun L; Zaidi M
    Ann N Y Acad Sci; 2010 Nov; 1211():107-12. PubMed ID: 21062299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Bisphosphonates for vascular calcification].
    Kurozumi A; Okada Y; Nakano K; Tanaka Y
    Clin Calcium; 2015 May; 25(5):723-8. PubMed ID: 25926576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bisphosphonates: indications in bone diseases other than osteoporosis].
    Abdelmoula LC; Ben M'barek R; Ben Hadj Yahia C; Tekaya R; Testouri N; Chaabouni L; Zouari R
    Tunis Med; 2011 Jun; 89(6):511-6. PubMed ID: 21681711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates' use in metastatic bone disease.
    Hubner RA; Houston SJ
    Hosp Med; 2005 Jul; 66(7):414-9. PubMed ID: 16025799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge?
    Neven EG; De Broe ME; D'Haese PC
    Kidney Int; 2009 Mar; 75(6):580-2. PubMed ID: 19247382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates in the treatment of osteoporosis: a review of skeletal safety concerns.
    Habib ZA
    Expert Rev Endocrinol Metab; 2017 Jan; 12(1):59-71. PubMed ID: 30058876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.
    Costa L
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis.
    Kranenburg G; Bartstra JW; Weijmans M; de Jong PA; Mali WP; Verhaar HJ; Visseren FLJ; Spiering W
    Atherosclerosis; 2016 Sep; 252():106-115. PubMed ID: 27513349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Regulation of calcification by bisphosphonates].
    Ono K; Wada S
    Clin Calcium; 2004 Jun; 14(6):60-3. PubMed ID: 15577056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial.
    Toussaint ND; Lau KK; Strauss BJ; Polkinghorne KR; Kerr PG
    Am J Kidney Dis; 2010 Jul; 56(1):57-68. PubMed ID: 20347511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and their influence on fracture healing: a systematic review.
    Molvik H; Khan W
    Osteoporos Int; 2015 Apr; 26(4):1251-60. PubMed ID: 25572046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
    Clézardin P
    Bone; 2011 Jan; 48(1):71-9. PubMed ID: 20655399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates in phenytoin-induced bone disorder.
    Khanna S; Pillai KK; Vohora D
    Bone; 2011 Mar; 48(3):597-606. PubMed ID: 21040807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteonecrosis of the jawbone as a side effect of intravenous treatment with bisphosphonates].
    Schortinghuis J; Witjes MJ; Spijkervet KL; de Visscher JG
    Ned Tijdschr Geneeskd; 2007 Feb; 151(5):314-8. PubMed ID: 17326477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catheter based inhibition of arterial calcification by bisphosphonates in an experimental atherosclerotic rabbit animal model.
    Synetos A; Toutouzas K; Benetos G; Drakopoulou M; Trantalis G; Kotronias R; Agrogiannis G; Tsiamis E; Deftereos S; Davlouros P; Patsouris E; Stefanadis C
    Int J Cardiol; 2014 Sep; 176(1):177-81. PubMed ID: 25042648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link between Bone and the Vasculature.
    Byon CH; Chen Y
    Curr Osteoporos Rep; 2015 Aug; 13(4):206-15. PubMed ID: 25947259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibitory effects of bisphosphonate on vascular calcification].
    Katsumata T
    Clin Calcium; 2002 Mar; 12(3):383-8. PubMed ID: 15775319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of osteonecrosis of the jaw in patients treated with bisphosphonate.
    Badel T; Pavicin IS; Carek AJ; Rosin-Grget K; Grbesa D
    Coll Antropol; 2013 Jun; 37(2):645-51. PubMed ID: 23941019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy.
    Li Q; Kingman J; Sundberg JP; Levine MA; Uitto J
    J Invest Dermatol; 2016 Jan; 136(1):275-283. PubMed ID: 26763447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.